Treatment of Heroin (Diamorphine) Addiction (original) (raw)

• Van der Burgh C. A review of the drug abuse situation in the world. National Institute on Drug Abuse. Community Epidemiology Work Group. In: Epidemiologic trends in drug abuse. Volume II: Proceeding of the International Epidemiology Work Group on Drug Abuse. Rockville (MD): National Institute on Drug Abuse, 1999: 135–8
  Google Scholar
• Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Summary of findings from 1998 National Household Survey on Drug Abuse, 1998 [online]. Available from URL: http://www.samhsa.gov/news/click3_frame.html [Accessed 2002 Apr 26]
• Sloboda Z. Drug abuse patterns in the United States. National Institute on Drug Abuse. Community Epidemiology Work Group. Epidemiologic trends in drug abuse. Volume II: Proceeding of the International Epidemiology Work Group on Drug Abuse. Rockville (MD): National Institute on Drug Abuse, 1999: 135–8
  Google Scholar
• Rounsaville BJ, Kosten TR. Treatment for opioid dependence: quality and access. JAMA 2000; 283(10): 1337–9
  Article PubMed CAS Google Scholar
• NIH Consensus Panel. Effective medical treatment of opiate addiction. National consensus development panel on effective medical treatment of opiate addiction. JAMA 1999; 280(22): 1936–43
  Google Scholar
• Ward J, Bell J, Mattick RP, et al. Methadone maintenance therapy for opioid dependence: a guide to appropriate use. CNS Drugs 1996; 6(6): 440–9
  Article CAS Google Scholar
• Margolin A, Kosten TR. Opioid detoxification and maintenance with blocking agents. In: Miller NS, editor. Comprehensive handbook of drug and alcohol addiction. New York (NY): Marcel Dekker, 1991: 1127–1147
  Google Scholar
• Senay EC, Dorus W, Goldberg F, et al. Withdrawal from methadone maintenance. Arch Gen Psychiatry 1977; 34: 361–7
  Article PubMed CAS Google Scholar
• Lowinson JH, Payte JT, Salsitz E, et al. Methadone maintenance. In: Lowinson JH, Ruiz P, Millman RB, et al., editors. Substance abuse: a comprehensive textbook. 3rd ed. Baltimore (MD): Williams and Wilkins, 1997: 405–15
  Google Scholar
• Rosenheck R, Kosten T. Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend 2001; 63: 253–62
  Article PubMed CAS Google Scholar
• Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence: a current perspective. West J Med 1990; 152: 588–99
  PubMed CAS Google Scholar
• Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York (NY): Springer-Verlag, 1991: 212–232
  Book Google Scholar
• Caplehorn JR, Dalton MS, Cluff MC, et al. Retention in methadone maintenance and heroin addicts’ risk of death. Addiction 1994; 89: 203–9
  Article PubMed CAS Google Scholar
• Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr S cand 1990; 82: 223–7
  Article CAS Google Scholar
• Gearing FR, Schweitzer MD. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. Am J Epidemiol 1974; 100: 101–12
  PubMed CAS Google Scholar
• Concool B, Smith H, Stimmel B. Mortality rates of persons entering methadone maintenance: a seven-year study. Am J Drug Alcohol Abuse 1979; 6: 345–53
  Article PubMed CAS Google Scholar
• Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction 1999; 94: 479–88
  Article PubMed CAS Google Scholar
• Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998; 26: 257–60
  PubMed CAS Google Scholar
• Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13: 957–62
  Article PubMed CAS Google Scholar
• Cooper JR. Including narcotic addiction treatment in an office-based practice. JAMA 1995; 273: 1619–20
  Article PubMed CAS Google Scholar
• Novick DM, Joseph H, Salsitz EA, et al. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians’ offices (medical maintenance): follow-up at three and a half to nine and a fourth years. J Gen Intern Med 1994; 9: 127–30
  Article PubMed CAS Google Scholar
• Novick DM, Pascarelli EF, Joseph H, et al. Methadone maintenance patients in general medical practice, a preliminary report. JAMA 1998; 259: 3299–302
  Article Google Scholar
• Opioid drugs in maintenance and detoxification treatment of opiate addiction. Substance Abuse and Mental Health Services Administration, HHS. Final rule. Fed Regist 2001 Jan 17; 66 (11): 4076–102
• Wilkerson D, Migas N, Slaven T. Outcome-oriented standards and performance indicators for substance dependency rehabilitation programs. Subst Use Misuse 2000; 35(12–14): 1679–703
  Article PubMed CAS Google Scholar
• Food and Drug Administration (FDA), MedWatch. ORLAAM. In: Index of safety-related drug labeling change summaries approved by FDA center for drug evaluation and research (CDER). Available from URL: http://www.fda.gov/medwatch/safety.htm [Accessed 2002 Apr 26]
• Judson BA, Goldstein A. Levo-alpha-acetylmethadol (LAAM) in the treatment of heroin addicts. I. Dosage schedule for induction and stabilization. Drug Alcohol Depend 1979; 4: 461–6
  Article PubMed CAS Google Scholar
• Ling W, Charuvastra C, Kaim SC, et al. Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study. Arch Gen Psychiatry 1976; 33: 709–20
  Article PubMed CAS Google Scholar
• Jones HE, Strain EC, Bigelow GE, et al. Induction with levomethadyl acetate: safety and efficacy. Arch Gen Psychiatry 1998; 55: 729–36
  Article PubMed CAS Google Scholar
• Eissenberg T, Bigelow GE, Strain EC, et al. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. A randomized clinical trial. JAMA 1997; 277: 1945–51
  Article PubMed CAS Google Scholar
• Tennant Jr FS, Rawson RA, Pumphrey E, et al. Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM). J Subst Abuse Treat 1986; 3: 195–202
  Article PubMed Google Scholar
• Judson BA, Goldstein A, Inturrisi CE. Methadyl acetate (LAAM) in the treatment of heroin addicts. II. Double-blind comparison of gradual and abrupt detoxification. Arch Gen Psychiatry 1983; 40: 834–40
  Article PubMed CAS Google Scholar
• Obadia Y, Perrin V, Feroni I, et al. Injecting misuse of buprenorphine among French drug users. Addiction 2001; 96: 267–72
  Article PubMed CAS Google Scholar
• Fudala PJ, Bridge TP, Herbert S, et al. A multisite efficacy evaluation of a buprenorphine/naloxone product for opiate dependence treatment. Rockville (MD): DHHS/NIH/NIDA. NIDA Res Monogr 1998; 179: 105
  Google Scholar
• Kuhlman Jr JJ, Levine B, Johnson RE, et al. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93: 549–59
  Article PubMed Google Scholar
• Rance MJ, Dickens JN. The influence of drug-receptor kinetics on the pharmacological and pharmaco-kinetic profiles of buprenorphine. In: Van Ree JM, Pereniums L, editors. Characteristics and function of opioids. Amsterdam: Elsevier/North-Holland Biomedical Press, 1978: 65–66
  Google Scholar
• Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001; 61: 173–81
  Article PubMed CAS Google Scholar
• Petry NM, Bickel WK, Badger GJ. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens. Addiction 2001; 96: 823–34
  Article PubMed CAS Google Scholar
• Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000; 58: 143–52
  Article PubMed CAS Google Scholar
• Walsh SL, Preston KL, Bigelow GE, et al. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995; 274: 361–72
  PubMed CAS Google Scholar
• Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55: 569–80
  Article PubMed CAS Google Scholar
• Lange WR, Fudala PJ, Dax EM, et al. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend 1990; 26: 19–28
  Article PubMed CAS Google Scholar
• Huestis MA, Umbricht A, Preston KL, et al. Safety of buprenorphine: no clinically relevant cardio-respiratory depression at high IV doses. In: Harris LS, editor. Problems of Drug Dependence. NIDA Res Monogr. Washington (DC): U.S. Government Printing Office 1999; 179: 62
  Google Scholar
• Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews [computer file] 2000, CD002025
• Umbricht A, Montoya ID, Hoover DR, et al. Naltrexone shortened opioid detoxification with buprenorphine. Drug Alcohol Depend 1999; 56: 181–90
  Article PubMed CAS Google Scholar
• Nigam A, Ray R, Tripathi BM. Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treat 1993; 10:391–4
  Article PubMed CAS Google Scholar
• Janiri L, Mannelli P, Persico AM, et al. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend 1994; 36: 139–45
  Article PubMed CAS Google Scholar
• Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 1994; 36: 115–21
  Article PubMed CAS Google Scholar
• O’Connor PG, Carroll KM, Shi JM, et al. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med 1997; 127: 526–30
  PubMed Google Scholar
• Bickel WK, Amass L. Buprenorphine treatment of opioid dependence: A review. Exp Clin Psychopharmacol 1995; (3): 477–89
• Bickel WK, Amass L, Higgins ST, et al. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. J Consult Clin Psychol 1997; 65: 803–10
  Article PubMed CAS Google Scholar
• Amass L, Bickel WK, Higgins ST, et al. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis 1994; 13: 33–45
  Article PubMed CAS Google Scholar
• Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93: 475–86
  Article PubMed CAS Google Scholar
• Resnick RB, Galanter M, Pycha C, et al. Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacol Bull 1992; 28: 109–13
  PubMed CAS Google Scholar
• Resnick RB, Resnick E, Galanter M. Buprenorphine responders: a diagnostic subgroup of heroin addicts? Prog Neuropsychopharmacol Biol Psychiatry 1991; 15: 531–8
  Article PubMed CAS Google Scholar
• Kosten TR, Morgan C, Kleber HD. Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 1991; 17: 119–28
  Article PubMed CAS Google Scholar
• Kosten TR, Schottenfeld R, Ziedonis D, et al. Buprenorphine versus methadone maintenance for opioid dependence, [see comments]. J Nerv Ment Dis 1993; 181: 358–64
  Article PubMed CAS Google Scholar
• Johnson RE, Chutuape MA, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependencefsee comments]. N Engl J Med 2000; 343: 1290–7
  Article PubMed CAS Google Scholar
• Vignau J, Brunelle E. Differences between general practitioner-and addiction centre-prescribed buprenorphine substitution therapy in France. Preliminary results. Eur Addict Res 1998; 4 Suppl. 1: 24–8
  Article PubMed Google Scholar
• Barrau K, Thirion X, Micallef J, et al. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction 2001; 96(10): 1433–41
  Article PubMed CAS Google Scholar
• Thirion X, Micallef J, Barrau K, et al. Recent evolution in opiate dependence in France during generalisation of maintenance treatments. Drug Alcohol Depend 2001; 61: 281–5
  Article PubMed CAS Google Scholar
• Tracqui A, Kintz P, Ludes B. Buprenorphine-Related deaths among drug addicts in France: Areport on 20 fatalities. J Anal Toxicol 1998; 22: 430–3
  PubMed CAS Google Scholar
• Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001; 121: 65–9
  Article PubMed CAS Google Scholar
• Stoller KB, Bigelow GE, Walsh SL, et al. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacologia 2001; 154: 230–42
  Article CAS Google Scholar
• Gold MS, Pottash AL. Endorphins, locus coerulus, clonidine and lofexidine: a mechanism for opiate withdrawal and new nonopiate treatments. Adv Alcohol Subst Abuse 1981; 1(1): 33–52
  Article CAS Google Scholar
• Washton AM, Resnick RB. Recent advances in opiate detoxification: clonidine and lofexidine. NIDA Res Monogr 1983; 43: 44–50
  PubMed CAS Google Scholar
• Bearn J, Gossop M, Strang J. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend 1998; 50: 227–32
  Article PubMed CAS Google Scholar
• Kahn A, Mumford JP, Rogers GA, et al. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend 1997; 44: 57–61
  Article PubMed CAS Google Scholar
• Gold MS, Redmond Jr DE, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 1978; 2: 599–602
  Article PubMed CAS Google Scholar
• Washton AM, Resnick RB. Clonidine for opiate detoxification: outpatient clinical trials. Am J Psychiatry 1980; 137: 1121–2
  PubMed CAS Google Scholar
• Charney DS, Sternberg DE, Kleber HD, et al. The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch Gen Psychiatry 1981; 38: 1273–7
  Article PubMed CAS Google Scholar
• Kleber HD, Riordan CE, Rounsaville B, et al. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry 1985; 42: 391–4
  Article PubMed CAS Google Scholar
• Asin KE, Wirtshafter D. Clonidine produces a conditioned place preference in rats. Psychopharmacology 1985; 85: 383–5
  Article PubMed CAS Google Scholar
• Davis WM, Smith SG. Catecholaminergic mechanisms of reinforcement: direct assessment by drug-self-administration. Life Sci 1977; 20: 483–92
  Article PubMed CAS Google Scholar
• Lauzon P. Two cases of clonidine abuse/dependence in methadone-maintained patients. J Subst Abuse Treat 1992; 9: 125–7
  Article PubMed CAS Google Scholar
• Lin SK, Strang J, Su LW, et al. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend 1997; 48: 127–33
  Article PubMed CAS Google Scholar
• Carnwath T, Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend 1998; 50: 251–4
  Article PubMed CAS Google Scholar
• Gerra G, Zaimovic A, Giusti F, et al. Lofexidine versus clonidine in rapid opiate detoxification. J Subst Abuse Treat 2001; 21: 11–7
  Article PubMed CAS Google Scholar
• Kleber HD, Topazian M, Gaspari J, et al. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 1987; 13: 1–17
  Article PubMed CAS Google Scholar
• Gowing L, Ali R, White J. Opioid antagonists and adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews [computer file] 2000, CD002021
• O’Connor PG, Waugh ME, Carroll KM, et al. Primary care-based ambulatory opioid detoxification: the results of a clinical trial. J Gen Intern Med 1995; 10: 255–60
  Article PubMed Google Scholar
• Gerra G, Marcato A, Caccavari R, et al. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat 1995; 12: 35–41
  Article PubMed CAS Google Scholar
• Gerra G, Zaimovic A, Rustichelli P, et al. Rapid opiate detoxication in outpatient treatment: relationship with naltrexone compliance. J Subst Abuse Treat 2000; 18: 185–91
  Article PubMed CAS Google Scholar
• Vining E, Kosten TR, Kleber HD. Clinical Utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addiction 1988; 83: 567–75
  Article CAS Google Scholar
• Loimer N, Schmid R, Presslich O, et al. Naloxone treatment for opiate withdrawal syndrome. Br J Psychiatry 1988; 153: 851–2
  Article PubMed CAS Google Scholar
• Loimer N, Schmid R, Lenz K, et al. Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. Br J Psychiatry 1990; 157: 748–52
  Article PubMed CAS Google Scholar
• O’Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques [see comments]. JAMA 1998; 279: 229–34
  Article PubMed Google Scholar
• Scherbaum N, Klein S, Kaube H, et al. Alternative strategies of opiate detoxification: evaluation of the so-called ultra-rapid detoxification. Pharmacopsychiatry 1998; 31: 205–9
  Article PubMed CAS Google Scholar
• Rabinowitz J, Cohen H, Tarrasch R, et al. Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug Alcohol Depend 1997; 47: 77–86
  Article PubMed CAS Google Scholar
• O’Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med 2000; 133: 40–54
  PubMed Google Scholar
• Cucchia AT, Monnat M, Spagnoli J, et al. Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. Drug Alcohol Depend 1998; 52: 243–50
  Article PubMed CAS Google Scholar
• San L, Puig M, Bulbena A, et al. High risk of ultrashort non-invasive opiate detoxification [letter]. Am J Psychiatry 1995; 152(6): 956
  PubMed CAS Google Scholar
• Pfab R, Hirtl C, Zilker T. Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure. J Toxicol Clin Toxicol 1999; 37: 43–50
  Article PubMed CAS Google Scholar
• Zielbauer P. State knew of risky heroin treatment before patient deaths. The New York Times 1999 Oct 31; Sect. 1:41 (col.2)
• Strang J, Bearn J, Gossop M. Opiate detoxification under anaesthesia [see comments]. BMJ 1997; 315: 1249–50
  Article PubMed CAS Google Scholar
• Albanese AP, Gevirtz C, Oppenheim B, et al. Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD). J Addict Dis 2000; 19: 11–28
  Article PubMed CAS Google Scholar
• Hensel M, Kox WJ. Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: a prospective study in methadone, heroin, codeine and morphine addicts. Acta Anaesthesiol Scand 2000; 44: 326–33
  Article PubMed CAS Google Scholar
• Lawental E. Ultra rapid opiate detoxification as compared to 30-day inpatient detoxification program-a retrospective follow-up study. J Subst Abuse 2000; 11: 173–81
  Article PubMed CAS Google Scholar
• Marrazzi MA, Wroblewski JM, Kinzie J, et al. High-dose naltrexone and liver function safety. Am J Addict 1997; 6: 21–9
  PubMed CAS Google Scholar
• Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews 2 (CD001333), 2001
• Shufman EN, Porat S, Witztum E, et al. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry 1994; 35: 935–45
  Article PubMed CAS Google Scholar
• Hollister LE. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the national research council committee on clinical evaluation of narcotic antagonists. Arch Gen Psychiatry 1978; 35(3): 335–40
  Article Google Scholar
• Curren S, Savage C. Patient response to naltrexone: issues of acceptance, treatment effects, and frequency of administration. NIDA Res Monogr 1976; 9: 67–9
  Google Scholar
• San L, Pomarol G, Peri JM, et al. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 1991; 86: 983–90
  Article PubMed CAS Google Scholar
• Lerner A, Sigal M, Bacalu A, et al. A naltrexone double blind placebo controlled study in Israel. Isr J Psychiatry Relat Sci 1992; 29: 36–43
  PubMed CAS Google Scholar
• Hulse GK, Basso MR. Reassessing naltrexone maintenance as a treatment for illicit heroin users. Drug Alcohol Rev 1999; 18(3): 263–9
  Article Google Scholar